千红制药
(002550)
| 流通市值：81.22亿 | | | 总市值：108.53亿 |
| 流通股本：9.58亿 | | | 总股本：12.80亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 638,549,089.41 | 439,945,400.01 | 637,459,832.53 | 546,180,633.46 |
| 应收票据及应收账款 | 314,799,510.25 | 257,029,633.75 | 273,302,446.26 | 309,782,029.38 |
| 其中：应收票据 | 3,783,072.31 | 2,641,997.26 | 2,514,328.63 | 3,799,184.82 |
| 应收账款 | 311,016,437.94 | 254,387,636.49 | 270,788,117.63 | 305,982,844.56 |
| 应收款项融资 | 27,259,994.02 | 17,216,529.34 | 22,696,364.06 | 36,043,139.09 |
| 预付款项 | 16,252,749.27 | 11,718,847.79 | 24,635,676.34 | 18,366,292.38 |
| 其他应收款合计 | 23,980,916.78 | 23,237,786.92 | 4,793,365.67 | 6,476,981.72 |
| 其中:应收利息 | - | - | 1,122,601.23 | 1,122,601.23 |
| 存货 | 367,041,802.35 | 426,812,563.07 | 390,770,971.42 | 456,032,492.73 |
| 一年内到期的非流动资产 | 240,000,000 | 192,897,931.42 | 110,000,000 | 20,899,800 |
| 其他流动资产 | 26,779,498.02 | 51,015,204.09 | 4,960,574.91 | 4,394,947.37 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,858,267,247.17 | 1,693,701,086.5 | 1,539,683,325.84 | 1,492,494,844.84 |
| 非流动资产: | | | | |
| 债权投资 | 110,858,223.92 | 155,431,737.87 | 285,397,007.18 | 200,165,027.38 |
| 长期股权投资 | 4,135,161.14 | 4,652,846.17 | 5,150,768.76 | 2,272,108.21 |
| 固定资产 | 487,940,434.24 | 502,346,927.78 | 514,585,372.05 | 528,280,938.17 |
| 在建工程 | 61,358,712.29 | 61,248,538 | 9,885,714.17 | 5,957,483.06 |
| 无形资产 | 108,704,679.11 | 109,324,944.41 | 110,256,205.24 | 111,185,113.57 |
| 开发支出 | 123,363,751.15 | 116,590,657.78 | 99,660,827.47 | 86,247,955.23 |
| 商誉 | 11,135,053.57 | 11,135,053.57 | 11,135,053.57 | 11,135,053.57 |
| 长期待摊费用 | 20,484,482.31 | 21,448,004.46 | 22,480,254.94 | 23,397,965.92 |
| 递延所得税资产 | 66,416,312.11 | 75,256,028.8 | 79,365,601.92 | 91,242,121.4 |
| 其他非流动资产 | 95,640,100 | 79,305,436 | 84,672,030.86 | 77,903,916.6 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,090,036,909.84 | 1,136,740,174.84 | 1,222,588,836.16 | 1,137,787,683.11 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,948,304,157.01 | 2,830,441,261.34 | 2,762,272,162 | 2,630,282,527.95 |
| 流动负债: | | | | |
| 短期借款 | 20,021,879.45 | 20,021,879.45 | 20,019,890.41 | 20,021,369.86 |
| 应付票据及应付账款 | 74,408,126.92 | 88,637,854.78 | 50,133,516.92 | 45,485,236.71 |
| 应付账款 | 74,408,126.92 | 88,637,854.78 | 50,133,516.92 | 45,485,236.71 |
| 合同负债 | 2,342,445.74 | 9,677,118.52 | 2,936,545.66 | 3,395,193.23 |
| 应付职工薪酬 | 14,673,095.24 | 35,420,125.88 | 28,944,567.81 | 21,625,848.73 |
| 应交税费 | 13,704,133.9 | 7,683,904.29 | 21,869,117.57 | 22,821,261.71 |
| 其他应付款合计 | 15,099,348.85 | 13,468,319.91 | 12,060,910.6 | 14,693,169.1 |
| 其他流动负债 | 41,577,808.43 | 48,478,782.21 | 49,047,565.33 | 48,993,672.43 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 181,826,838.53 | 223,387,985.04 | 185,012,114.3 | 177,035,751.77 |
| 非流动负债: | | | | |
| 递延收益 | 88,205,537.08 | 86,460,537.4 | 88,321,037.83 | 90,181,538.14 |
| 递延所得税负债 | 3,994,146.66 | 4,022,100.52 | 4,039,061.45 | 4,217,323.4 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 92,199,683.74 | 90,482,637.92 | 92,360,099.28 | 94,398,861.54 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 274,026,522.27 | 313,870,622.96 | 277,372,213.58 | 271,434,613.31 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,279,800,000 | 1,279,800,000 | 1,279,800,000 | 1,279,800,000 |
| 资本公积 | 41,653,809.86 | 41,653,809.86 | 41,653,809.86 | 41,653,809.86 |
| 减:库存股 | 170,863,806.25 | 170,863,806.25 | 170,863,806.25 | 170,863,806.25 |
| 其他综合收益 | -2,320,721.76 | -2,418,530.75 | 495,404.21 | -386,023.7 |
| 盈余公积 | 327,210,615.91 | 327,210,615.91 | 289,236,431.28 | 289,236,431.28 |
| 未分配利润 | 1,203,028,916.65 | 1,042,060,518.73 | 1,033,587,852.64 | 906,795,040.55 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,678,508,814.41 | 2,517,442,607.5 | 2,473,909,691.74 | 2,346,235,451.74 |
| 少数股东权益 | -4,231,179.67 | -871,969.12 | 10,990,256.68 | 12,612,462.9 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,674,277,634.74 | 2,516,570,638.38 | 2,484,899,948.42 | 2,358,847,914.64 |
| 负债和股东权益合计 | 2,948,304,157.01 | 2,830,441,261.34 | 2,762,272,162 | 2,630,282,527.95 |
| 公告日期 | 2025-04-19 | 2025-04-19 | 2024-10-18 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |